dc.contributor | Quijano Nieto, Bernardo Alfonso | |
dc.contributor | Amaya Nieto, Javier Antonio | |
dc.creator | Giraldo Toro, Daniel Eduardo | |
dc.date.accessioned | 2023-01-17T15:52:31Z | |
dc.date.accessioned | 2023-06-07T00:08:07Z | |
dc.date.available | 2023-01-17T15:52:31Z | |
dc.date.available | 2023-06-07T00:08:07Z | |
dc.date.created | 2023-01-17T15:52:31Z | |
dc.date.issued | 2023-01-16 | |
dc.identifier | https://repositorio.unal.edu.co/handle/unal/82978 | |
dc.identifier | Universidad Nacional de Colombia | |
dc.identifier | Repositorio Institucional Universidad Nacional de Colombia | |
dc.identifier | https://repositorio.unal.edu.co/ | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/6651754 | |
dc.description.abstract | Antecedentes: las leucemias y linfomas pueden causar cambios en la mácula significativos.
Hace falta evidencia para comprender las repercusiones en oftalmología y hematología. La
tomografía de coherencia óptica (OCT) es una imagen no invasiva que detalla alteraciones en
cada capa de la retina, sin embargo, la literatura carece de estudios guiados por OCT en esta
población.
Objetivo: Describir las alteraciones maculares, identificadas en OCT, de pacientes con
leucemias y linfomas, en población adulta que asistió a la Clínica Oftalmocenter y Clínica de
ojos en el periodo 2017-2022.
Métodos: estudio descriptivo, retrospectivo con pacientes de la base de datos de historias
clínicas, en las instituciones involucradas, con historia de leucemia o linfoma, que ya tuvieran
OCT de mácula realizada.
Resultados: se incluyeron un total de 139 ojos de 120 pacientes, con edad media de 42.2 años
(DE=18.4). La mayoría de pacientes tuvieron diagnóstico de Leucemia Linfoide Aguda (45.7%
[n=64]), seguido por Linfoma No Hodgkin (31.4%[n=44]). La ventana diagnóstico hematológico
- toma de OCT fue mayor en ojos sin alteraciones comparado con los ojos alterados (287 vs
222 días respectivamente). Las OCT alteradas representaron el 18,7% del total de ojos. En el
53,8% de las OCT alteradas, la fundoscopía no detectó lesiones.
Conclusiones: las leucemias y linfomas pueden dar cambios en la macula que, en más del
50% no son visibles con fundoscopía. El 18,7% de los ojos tenían alteraciones, esta frecuencia
puede ser mayor dado que los pacientes tenían una sola OCT. Se requiere un estudio
multicéntrico, donde se realice OCT seriada y seguimiento de varios años para comprender el
desempeño y utilidad de estas imágenes (Texto tomado de la fuente) | |
dc.description.abstract | Background
Leukemia and lymphoma can cause significant macular changes. There is lack of evidence to
understand the implications for ophthalmologists and hematologists. Optical Coherence
Tomography (OCT) is a noninvasive image modality that shows each retinal layer, however,
there are currently no studies on this population guided by OCT.
Objective
To describe macular alterations, identified by OCT, on adults with leukemia or lymphoma that
assisted to eye clinics (Oftalmocenter and Clínica de Ojos) throughout 2017 to 2022.
Methods
We conducted a descriptive, retrospective study with patients filtered from the eye clinics data
base that had history of leukemia or lymphoma and a macular OCT already taken.
Results
There were 139 eyes included from 120 patients. The median age was 42,2 years (SD=18.4).
The majority of patients had a diagnosis of Acute Lymphoblastic Leukemia (45.7% [n=64]), and
Non-Hodgkin Lymphoma (31.4%[n=44]). The hematological diagnosis to OCT images time
window was longer on eyes without alterations versus those with macular changes (287 vs 222
days respectively). The altered OCTs represented 18,7% of the total of eyes, and 53,8% of the
OCTs with alterations, had no lesions registered during fundoscopy.
Conclusions
Leukemia and lymphoma can cause macular changes, that in more than 50% of cases are not
visible on fundoscopy. The 18,7% of the total of eyes had OCT alterations, this frequency could
be higher because our patients only had OCT taken once. There is need for a multicentric study
where serial OCTs and following of each patient during several years could be achieved, to
understand the performance and usefulness of this images | |
dc.language | spa | |
dc.publisher | Universidad Nacional de Colombia | |
dc.publisher | Bogotá - Medicina - Especialidad en Oftalmología | |
dc.publisher | Facultad de Medicina | |
dc.publisher | Bogotá, Colombia | |
dc.publisher | Universidad Nacional de Colombia - Sede Bogotá | |
dc.relation | Kasper, D.L., & Harrison, T. R. (2016). Harrison’s principles of internal medicine. New York: McGraw-Hill, Medical Pub. Division. (L. Kasper, Fauci, Hauser, Longo, Jameson (Ed.); 19th ed. | |
dc.relation | C. Rozman, F. C. (2020). Medicina Interna de Farreras y Rozman (19th ed.). Elsevier. | |
dc.relation | Li, J., Smith, A., Crouch, S., Oliver, S., Roman, E., & Smith, A. (2016). Estimating the prevalence of hematological malignancies and precursor conditions using data from Haematological Malignancy Research Network ( HMRN ). Cancer Causes & Control, 27(8), 1029–1036. https://doi.org/10.1007/s10552-016-0780-z. | |
dc.relation | Koshy, J., John, M., Thomas, S., Kaur, G., Batra, N., & Xavier, W. (2015). Ophthalmic manifestations of acute and chronic leukemias presenting to a tertiary care center in India. Indian Journal of Ophthalmology, 63(8), 659–664. | |
dc.relation | Damato B, Singh Arun. Clinical Ophthalmic Oncology. Uveal Tumors. Springer 3th edition. 2019. | |
dc.relation | Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug. 59(4):225-49. | |
dc.relation | Alvarnas JC, Brown PA, Aoun P, et al. Acute lymphoblastic leukemia. J Natl Compr Cancer Netw. 2012;10:858–914. | |
dc.relation | Eliassi-Rad B, Albert DM, Green WR. Frequency of ocular metastases in patients dying of cancer in eye bank populations. Br J Ophthalmol. 1996;80:125–8. | |
dc.relation | Batista J.L, Epstein M.M, Birmann B.M. Epidemiology of Hematologic Malignancies. Springer 2017. | |
dc.relation | Schachat AP, Markowitz JA, Guyer DR, et al. Ophthalmic manifestations of leukemia. Arch Ophthalmol. 1989;107:697–700. | |
dc.relation | Reddy SC, Jackson N, Menon BS. Ocular involvement in leukemia–a study of 288 cases. Ophthalmologica. 2003;217:441–445. | |
dc.relation | Holt, J. M., & Gordon-Smith, E. C. (1969). Retinal abnormalities in diseases of the blood. The British journal of ophthalmology, 53(3), 145–160. | |
dc.relation | Freeman LN, Schachat AP, Knox DL, et al. Clinical features, laboratory investigations, and survival in ocular reticulum cell sarcoma. Ophthalmology. 1987;94:1631–1639. | |
dc.relation | Lin P, Mruthyunjaya P. Retinal Manifestations of Oncologic and Hematologic Conditions. International Ophthalmology Clinics. 2012;52:67-91. | |
dc.relation | Shields C, Materin M. Review of Optical Coherence Tomography for Intraocular Tumors. Current Opinion in Ophthalmol. 2005;16:141—154. | |
dc.relation | Damato B, Singh Arun. Clinical Ophthalmic Oncology. Retinal Tumors. Springer 3th edition. 2019. | |
dc.relation | Arevalo JF, Fernandez CF, Garcia RA. Optical coherence tomography characteristics of choroidal metastasis. Ophthalmology. 2005;112(9):1612–9. | |
dc.relation | Al-Dahmash SA, Shields CL, Kaliki S, et al. Enhanced depth imaging optical coherence tomography of choroidal metastasis in 14 eyes. Retina. 2014;34(8):1588–93. | |
dc.relation | Demirci H, Cullen A, Sundstrom JM. Enhanced depth imaging optical coherence tomography of choroidal metastasis. Retina. 2014;34(7):1354–9. | |
dc.relation | Mapelli C, Invernizzi A, Barteselli G, et al. Multimodal imaging of vitreoretinal lymphoma. Ophthalmologica. 2016;236(3):166–74. | |
dc.relation | Barry RJ, Tasiopoulou A, Murray PI, et al. Characteristic optical coherence tomography findings in patients with primary vitreoretinal lymphoma: a novel aid to early diagnosis. Br J Ophthalmol. 2018;102:1362. | |
dc.relation | Damato B, Singh Arun. Clinical Ophthalmic Oncology Basic Principles. Springer 3th edition. 2019. | |
dc.relation | Jackson N, Reddy SC, Harun MH, et al. Macular haemorrhage in adult acute leukaemia patients at presentation and the risk of subsequent intracranial haemorrhage. Br J Haematol. 1997;98:204–209. | |
dc.relation | Ryan S, Schachat A. Ryan's Retina. Edinburgh, 6ta Ed. Elsevier; 2018. | |
dc.relation | Li J, Smith A, Crouch S, Oliver S, Roman E, Smith A. Estimating the prevalence of hematological malignancies and precursor conditions using data from Haematological Malignancy Research Network ( HMRN ). Cancer Causes Control. 2016;27(8):1029–36. | |
dc.relation | Eliassi-rad B, Albert DM, Green WR. Frequency of ocular metastases in patients dying of cancer in eye bank populations. 1996;125–8. | |
dc.relation | Ahmed YAAR, Eltayeb A. Clinical challenges: mieloma and concomitant type 2 diabetes. Int J Hematol Oncol Stem Cell Res 2013; 7: 34–41. | |
dc.relation | Gurunadh VS, Baijal V, PalitMG, Sarma YS. Bilateral simultaneous retinal vein occlusion. Indian J Ophthalmol 1999; 47: 248–250. | |
dc.relation | ZiaeiM, ElgoharyMA, Bremner FD. Bilateral central retinal vein occlusion in multiple myeloma. Can J Ophthalmol 2013; 48: 24–25. | |
dc.relation | Kurup SP, Khan S, Gill MK. SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY IN THE EVALUATION AND MANAGEMENT OF INFECTIOUS RETINITIS. 2014;2233–41. | |
dc.relation | Kincaid MC, Green WR. Ocular and orbital involvement in leukemia. Surv Ophthalmol. 1983;27:211–232 | |
dc.relation | Karesh JW, Goldman EJ, Reck K, et al. A prospective ophthalmic evaluation of patients with acute myeloid leukemia: correlation of ocular and hematologic findings. J Clin Oncol. 1989;7:1528. | |
dc.relation | Ministerio de Salud. Observatorio Nacional de Cáncer. Guía Metodológica 2018. Dirección de Epidemiología y Demografía, dirección de promoción y prevención. | |
dc.relation | Instituto Nacional de Cancerología ESE. Análisis de la Situación del Cáncer en Colombia 2015. Primera edición. Bogotá DC: Instituto Nacional de Cancerología ESE; 2017. | |
dc.relation | Torres Guzmán, M. D., Izquierdo Gracia, D. F., Torres Mejía, A., & Vallejo, J. M. (2016). Mieloma múltiple, lo que un radiólogo debe saber; Multiple Myeloma, What a Radiologist Should Know. Rev. Colomb. Radiol, 27(2), 4441–4450. | |
dc.relation | Kim K, Khang D. Past, Present, and Future of Anticancer Nanomedicine. 2020. International Journal of Nanomedicine. | |
dc.relation | Beaver J, Howie L. A 25-year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics. 2018. JAMA Oncology. | |
dc.relation | Ksiaa I, Kechida M, Zina S. Acute Lymphoblastic Leukemia Relapse presenting as retinal vasculitis. Clin Case Rep 2020;8:1467–1471. | |
dc.relation | Wong BJ, Berry JL. Acute lymphoblastic leukemia relapse presenting as optic nerve infiltration. JAMA Ophthalmol. 2017;135(1):e164656. | |
dc.relation | Ministerio de Salud y Protección Social. Resolución 8430 de 1993. Artículo 10, pp. 3. Bogotá DC; 1993. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/RESOLUCION-8430-DE-1993.PDF | |
dc.relation | Asociación Médica Mundial. Declaración de Helsinki de la AMM – Principios éticos para las investigaciones médicas en seres humanos. Fortaleza; 2013. Disponible en: https://www.wma.net/es/policies-post/declaracion-de-helsinkide-la-amm-principios-eticos-para-las-investigaciones-medicas-en-sereshumanos | |
dc.relation | Congreso de la República de Colombia. Ley Estatutaria 1581 de 2012. Artículos 5 y 6, pp. 4. [Internet] Bogotá DC; 2012. Disponible en: https://www.defensoria.gov.co/public/Normograma%202013_html/Normas/Ley_1581_2012.pdf. | |
dc.relation | Organización Panamericana de la Salud (OPS/OMS), Consejo de Organizaciones Internacionales de las Ciencias Médicas (CIOMS). Pautas éticas internacionales para la investigación relacionada con la salud con seres humanos, 4° Edición. [Internet] Ginebra: CIOMS; 2016. Disponible en: cioms.ch/wp-content/uploads/2017/12/CIOMSEthicalGuideline_SP_INTERIOR-FINAL.pdf | |
dc.relation | Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016. | |
dc.relation | Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia (review). J Clin Oncol. 2011;29(5):532–543. | |
dc.relation | Parikh, S. A. (2018). Chronic lymphocytic leukemia treatment algorithm 2018. Blood Cancer Journal, 8(10). | |
dc.relation | RIVOALEN, A., & LE XUAN CHAT. (1962). Chronic myeloid leukemia in children. La Médecine Infantile, 69, 427–436. | |
dc.relation | Hermans J, Krol AD, van Groningen K, Kluin PM, Kluin-Nelemans JC, Kramer MH, Noordijk EM, Ong F, Wijermans PW. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood. 1995 Aug 15;86(4):1460-3. | |
dc.rights | Atribución-NoComercial-SinDerivadas 4.0 Internacional | |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.title | Hallazgos de tomografía de coherencia óptica de la mácula y su correlación clínica con leucemias y linfomas en la población adulta | |
dc.type | Trabajo de grado - Especialidad Médica | |